Nasal foralumab for slowing progression in ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a new nasal spray medicine called foralumab to see if it is safe and can slow down ALS. The trial is part of the Healey ALS platform and uses special scans to check how the medicine affects the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have been diagnosed with ALS (Lou Gehrig's disease).
- Your blood neurofilament level (a marker of nerve damage) must be above 40 pg/mL.
- Your first symptoms of weakness or stiffness from ALS must have started within the last 24 months.
- Your breathing capacity must be at least 65% of what's expected for your age, gender, and height.
- If you take the ALS medications riluzole or edaravone, the dose must have been stable for at least 30 days.
- You must be able to travel to the study site for visits, and if you agree to them, safely undergo a lumbar puncture (spinal tap) or a PET scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.
This trial tests a new drug called kamlanoflast to see if it can slow the progression of ALS. It is for people with a recent diagnosis who are showing signs of active disease, and it may help reduce nerve damage.
This trial tests two new medicines (galunisertib and nerandomilast) together in people with a specific type of ALS. The combination may slow down the damage in the nervous system, and the trial is looking at whether it's safe and helps.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and whether it can slow the progression of the disease.
This study provides access to an experimental nasal spray medication called foralumab for people with a specific type of MS that has stopped responding to standard treatments. The goal is to see if the drug can slow or stop disability progression.
This trial tests a nasal spray medication, foralumab, to see if it can help people with non-active secondary progressive multiple sclerosis. It is only for people who completed a previous related study (TILS-021).
Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.